|
業務類別
|
Biotechnology |
|
業務概覽
|
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease. |
| 公司地址
| 9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705 |
| 電話號碼
| +1 240 399-4900 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.nextcure.com |
| 員工數量
| 40 |
| Mr. Michael S. Richman |
President, Chief Executive Officer and Director |
美元 609.26K |
24/04/2026 |
| Mr. Kevin G. Shaw |
Senior Vice President and General Counsel |
-- |
24/04/2026 |
| Dr. Sourav Kundu, PhD |
Senior Vice President, Development and Manufacturing |
-- |
24/04/2026 |
| Dr. Timothy Mayer, PhD |
Chief Operating Officer |
-- |
24/04/2026 |
| Mr. Steven P. Cobourn, C.P.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
24/04/2026 |
| Dr. Udayan Guha, M.D.,PhD |
Chief Medical Officer |
美元 474.19K |
24/04/2026 |
|
|
| Mr. Stephen W. Webster |
Independent Director |
24/04/2026 |
| Dr. John G. Houston, PhD |
Independent Director |
24/04/2026 |
| Mr. Michael S. Richman |
President, Chief Executive Officer and Director |
24/04/2026 |
| Dr. David S. Kabakoff,PhD |
Chairman of the Board |
24/04/2026 |
| Dr. Elaine V. Jones, PhD |
Independent Director |
24/04/2026 |
| Dr. Anne Borgman, M.D. |
Independent Director |
24/04/2026 |
| Dr. Ellen G. Feigal, M.D. |
Independent Director |
24/04/2026 |
|
|
|
|
